Back to Stocks

OGN

Organon & Co.
7 filings tracked
healthcarebiotechnologyLARGE ($10B-200B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Organon is successfully transitioning from a legacy spinoff into a lean, cash-generative healthcare platform. The first quarter of 2026 highlights a significant operational inflection, with net income surging 68% to $146 million and diluted EPS rising to $0.55.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a lean transformation, Organon's underlying operating engine shows signs of deterioration.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every OGN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a critical crossroads, balancing impressive short-term margin expansion against systemic long-term risks. On one hand, Organon has successfully optimized its cost structure and generated record operating cash flow of $225 million, transforming its bottom line through asset divestitures and rigorous expense control. The surge in biosimilar adoption provides a credible path toward sustainable growth, suggesting the business model is evolving toward a more modern, specialized pharmaceutical profile. However, the sustainability of this turnaround is heavily tethered to the successful completion of the Sun Pharma merger. Without this transaction, Organon must confront a daunting debt maturity profile and the operational drag of declining legacy brands. The presence of material weaknesses in internal controls and an active SEC probe adds a layer of regulatory risk that could complicate the merger's closing or impact investor confidence. Ultimately, the filing reveals a company that has cleaned up its balance sheet and trimmed its costs, but still requires a strategic partner to solve its scale and debt challenges.

Selected Quarter

Core Takeaway

Organon has achieved a bottom-line turnaround through cost-cutting and divestitures, but its long-term survival depends on the Sun Pharma merger to resolve a $8.5B debt burden.

Investor Lens

The trade-off is between the immediate value of the merger premium and the risk of a 'merger-or-nothing' scenario where failure to close leads to a debt crisis.

Watch Next

The stockholders' vote and regulatory approvals for the Sun Pharma merger agreement.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.08Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat
80%
bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition
90%
bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression
60%
bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action
70%
neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure
40%
bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat
80%
bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition
90%
bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression
60%
bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action
70%
neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure
40%
bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat
80%
bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition
90%
bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression
60%
bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action
70%
neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure
40%
bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat
80%
bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition
90%
bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression
60%
bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action
70%
neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure
40%
bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat
80%
bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition
90%
bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression
60%
bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action
70%
neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure
40%
bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat
80%
bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition
90%
bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression
60%
bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action
70%
neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure
40%
bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat
80%
bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition
90%
bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression
60%
bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action
70%
neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure
40%

Filing History

10-QMay 4, 2026
Expand Sequence

The Q1 2026 filing presents a company at a critical crossroads, balancing impressive short-term margin expansion against systemic long-term risks. On one hand, Organon has successfully optimized its cost structure and generated record operating cash flow of $225 million, transforming its bottom line through asset divestitures and rigorous expense control. The surge in biosimilar adoption provides a credible path toward sustainable growth, suggesting the business model is evolving toward a more modern, specialized pharmaceutical profile. However, the sustainability of this turnaround is heavily tethered to the successful completion of the Sun Pharma merger. Without this transaction, Organon must confront a daunting debt maturity profile and the operational drag of declining legacy brands. The presence of material weaknesses in internal controls and an active SEC probe adds a layer of regulatory risk that could complicate the merger's closing or impact investor confidence. Ultimately, the filing reveals a company that has cleaned up its balance sheet and trimmed its costs, but still requires a strategic partner to solve its scale and debt challenges.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.